Non-traditional adipokines in pediatric HIV-related lipodystrophy: a-FABP as a biomarker of central fat accumulation

References

• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48–62.
   PubMed Web of Science ®Google Scholar
• Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961–76.
   PubMedGoogle Scholar
• Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012;59:314–24.
   Google Scholar
• Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004;114: e235–42.
   PubMed Web of Science ®Google Scholar
• Resino S, Micheloud D, Lorente R, Bellon JM, Navarro ML, Munoz-Fernandez MA. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med 2011;12:54–60.
   Google Scholar
• Ramalho LC, Gonçalves EM, de Carvalho WR, Guerra-Junior G, Centeville M, Aoki FH, Morcillo AM, dos Santos Vilela MM, da Silva MT. Abnormalities in body composition and nutritional status in HIV-infected children and adolescents on antiretroviral therapy. Int J STD AIDS 2011;22:453–6.
   Google Scholar
• Spoulou V, Kanaka-Gantenbein C, Bathrellou I, Mora S, Mostrou G, Sidossis L, Chrousos G, Theodoridou M. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. Hormones (Athens) 2011;10:149–55.
   Google Scholar
• Viganò A, Zuccotti GV, Cerini C, Stucchi S, Puzzovio M, Giacomet V, Mora S. Lipodystrophy, insulin resistance, and adiponectin concentration in HIV-infected children and adolescents. Curr HIV Res 2011;9:321–6.
   Google Scholar
• Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–62.
   PubMed Web of Science ®Google Scholar
• Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-Binding Protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006;354:2552–63.
   PubMed Web of Science ®Google Scholar
• Kanaka-Gantenbein C, Margeli A, Pervanidou P, Sakka S, Mastorakos G, Chrousos GP, Papassotiriou I. Retinol-Binding Protein 4 and Lipocalin-2 in childhood and adolescent obesity: when children are not just ‘small adults’. Clin Chem 2008;54:1176–82.
   PubMed Web of Science ®Google Scholar
• Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:2287–93.
   PubMed Web of Science ®Google Scholar
• Lee D-C, Lee J-W, Im J-A. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabol Clin Exper 2007;56: 327–31.
   PubMed Web of Science ®Google Scholar
• Esteve E, Ricart W, Fernandez-Real JM. Adipocytokines and insulin resistance. The possible role of lipocalin-2, retinol binding protein-4 and adiponectin. Diabetes Care 2009; 32(suppl. 2):S362–7.
   Google Scholar
• Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537–43.
   PubMed Web of Science ®Google Scholar
• Escoté X, Megia A, López-Dupla M, Miranda M, Veloso S, Alba V, Domingo P, Pardo P, Viladés C, Peraire J, Giralt M, Richart C, Vendrell J, Vidal F. HIV-1 Lipodystrophy Study Group. A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy. HIV Med 2011;12:428–37.
   Google Scholar
• Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragonés G, Parra S, Girona J, Masana L. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008;199:147–53.
   PubMedGoogle Scholar
• Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006;55:221–7.
   PubMed Web of Science ®Google Scholar
• Kyrgios I, Galli-Tsinopoulou A, Stylianou C, Papakonstantinou E, Arvanitidou M, Haidich AB. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism 2012; 61:562–8.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.
   PubMed Web of Science ®Google Scholar
• Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011;165: 703–11.
   PubMed Web of Science ®Google Scholar
• Landrø L, Damås JK, Flo TH, Heggelund L, Ueland T, Tjønnfjord GE, Espevik T, Aukrust P, Frøland SS. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol 2008;152:57–63.
   PubMed Web of Science ®Google Scholar
• Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008;173:130–43.
   PubMed Web of Science ®Google Scholar